Trial Profile
Alogliptin, a dipeptidyl peptidase-4 inhibitor, improves postprandial endothelial dysfunction and postprandial triglycaemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2012
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary)
- Indications Atherosclerosis; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 12 Sep 2012 New trial record
- 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.